Status:

COMPLETED

Clinical Validation Plan of Capsular Tension Ring

Lead Sponsor:

Eyebright Medical Technology (Beijing) Co., Ltd.

Conditions:

Intraocular Lens Implantation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Through follow-up for 1 year or more, the safety and effectiveness of the Capsular Tension Ring produced by Eyebright Medical Technology (Beijing) Co., Ltd. were verified, which is used for intraocula...

Detailed Description

According to the principle of "Quality management standard for clinical trials of medical devices" issued by CFDA, a multi-center, randomized, open, positive product, parallel controlled trial design ...

Eligibility Criteria

Inclusion

  • Over 18 years old, no gender limit;
  • For cataract patients who are expected to undergo phacoemulsification + Capsular Tension Ring and intraocular lens implantation, the hardness of the surgical eye nucleus is 1 to 3;
  • Be able to understand the purpose of the trial, voluntarily participate in and sign informed consent form by the patient himself or his legal guardian.

Exclusion

  • Inclusion criteria
  • Over 18 years old, no gender limit;
  • For cataract patients who are expected to undergo phacoemulsification + Capsular Tension Ring and intraocular lens implantation, the hardness of the surgical eye nucleus is 1 to 3;
  • Be able to understand the purpose of the trial, voluntarily participate in and sign informed consent form by the patient himself or his legal guardian.
  • Exclusion criteria
  • The surgical eye has other ocular diseases, those with Capsular Tension Ring implantation or intraocular operation contraindications, such as binocular congenital cataracts, microphthalmia, children under the age of 12 months, corneal dystrophy or endothelial cell insufficiency, chronic uveitis, active ocular diseases (Diabetic retinopathy active stage, uncontrollable glaucoma), fragile capsular bag, zonular rupture exceeding 120 degrees, etc.
  • Accompanied by severe or unstable heart, liver, kidney, lung, endocrine (including thyroid insufficiency), blood, mental and nerve dysfunction and other diseases;
  • The surgical eye has had retinal detachment or retinopathy;
  • Patients with congenital cataracts undergoing operation;
  • Those whose electrocardiogram examination or laboratory examination results suggest surgical contraindications;
  • Those who are unsupervised or cannot follow the doctor's advice;
  • Those with a history of intraocular operation in the last 3 months;
  • It is estimated that the best corrected distance visual acuity after operation is less than 20/40;
  • Those who need combined eye operation;
  • Participated in clinical trials of other drugs or medical devices within 30 days before screening;
  • Patients who are using or need to use ocular or systemic drugs during the research period that may affect their visual acuity;
  • Pregnant or breastfeeding women;
  • Those who have been judged by the researcher to ignore the function of the contralateral eye;
  • The researcher judges that the patient is not suitable for other situations.

Key Trial Info

Start Date :

May 21 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 24 2017

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT04880018

Start Date

May 21 2015

End Date

October 24 2017

Last Update

May 10 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.